Analyzing the atai Life Sciences IPO
Business Trip, a podcast about psychedelic entrepreneurship
Welcome back to Business Trip, a podcast about psychedelic entrepreneurship! 🍄
Episode 9 features three experts, Josh Hardman, Michael Haichin, and Graham Pechenik as they analyze atai’s S-1 in advance of their IPO.
In this episode, we discuss:
How atai went from idea to IPO in 3 years
An overview of atai’s drug development programs and enabling technologies
The platform’s strategy and risks
Listen to the episode here, on Spotify or Apple Podcasts.
When you’re done listening, tweet at us @businesstripfm to share your thoughts!
Financial disclaimer: Please do your own research. This is not financial advice and the views shared are for information and entertainment purposes.
Business Trip tells the story of the emerging industry of psychedelics. Each episode features a new company in the field, ranging from biotech startups developing novel compounds, to clinics and retreats for healing, to software companies building tools to power the ecosystem.
Business Trip is produced by Greg Kubin and Matias Serebrinsky — we’re advocates of the healing powers of psychedelic medicine and see a bright future ahead for the industry.
Thanks for listening,
💖 Know someone who would enjoy Business Trip?